Gluskin Sheff & Assoc Inc Regeneron Pharmaceuticals, Inc. Transaction History
Gluskin Sheff & Assoc Inc
- $814 Million
- Q3 2024
A detailed history of Gluskin Sheff & Assoc Inc transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Gluskin Sheff & Assoc Inc holds 2,234 shares of REGN stock, worth $1.54 Million. This represents 0.29% of its overall portfolio holdings.
Number of Shares
2,234
Previous 2,234
-0.0%
Holding current value
$1.54 Million
Previous $2.35 Million
-0.0%
% of portfolio
0.29%
Previous 0.28%
Shares
10 transactions
Others Institutions Holding REGN
# of Institutions
1,496Shares Held
82.8MCall Options Held
1.22MPut Options Held
1.51M-
Vanguard Group Inc Valley Forge, PA9.32MShares$6.41 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$5.8 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY7.49MShares$5.15 Billion0.64% of portfolio
-
State Street Corp Boston, MA4.9MShares$3.37 Billion0.21% of portfolio
-
Capital World Investors Los Angeles, CA4.3MShares$2.95 Billion0.72% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $73.7B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...